Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2022 - 08 - 10

National Health Commission: azvidin tablets were included in the diagnosis and treatment plan of nov

On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnosis and treatment scheme for novel coronavirus pneumonia (Ninth Edition) through research. The details are as follows:1、 Drug name: Azivudine 2、 Indications It is used to treat adu...

浏览次数：4575

查看详情>>

发布时间: 2022 - 08 - 05

The successful submission of the first share of the new crown oral drug is welcomed by The Hong Kong

Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution to accompany the growth of Genuine Biotech, and it has led two consecutive rounds of investment for the company. The first was in November 2020, when it exclusively led the series A financing of Genu...

浏览次数：5650

查看详情>>

发布时间: 2022 - 08 - 01

Apexigen successfully listed on Nasdaq!

Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of Nasdaq successfully and presented in stock code “APGN” this evening, August 1st, Beijing time. In July 2018, Efung Capital was one of the players of Apexigen's Series C financing.Headquartere...

浏览次数：503

查看详情>>

发布时间: 2022 - 07 - 25

China's first new crown oral drug has been approved for marketing!

On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumonia has been approved.This is China's first oral anti-COVID-19 drug with entirely autonomous intellectual property rights.

浏览次数：5567

查看详情>>